EGFR and non-small cell lung carcinoma: AURKB was reported as a potential target in non-small cell lung cancer (NSCLC) with anti-EGFR resistance 54 and AURKB inhibitors reportedly could also help to overcome cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) 30.